Coiante Scott M 4
4 · Aprea Therapeutics, Inc. · Filed Mar 1, 2021
Insider Transaction Report
Form 4
Coiante Scott M
SVP, Chief Financial Officer
Transactions
- Award
Stock Option (right to Buy)
2021-02-25+143,000→ 143,000 totalExercise: $6.00Exp: 2031-02-25→ Common Stock (143,000 underlying) - Award
Common Stock
2021-02-25+33,000→ 35,500 total - Award
Common Stock
2021-02-25+63,500→ 99,000 total
Footnotes (3)
- [F1]These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 11,000 shares on February 25, 2022, (ii) 11,000 shares on February 25, 2023 and (iii) 11,000 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
- [F2]These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 21,166 shares on August 25, 2021, (ii) 21,167 shares on February 25, 2022 and (iii) 21,167 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
- [F3]Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.